Crinetics Pharmaceuticals (CRNX) is back in focus after presenting extensive new data at the Endocrine Society’s 2026 meeting, covering both its approved acromegaly drug PALSONIFY and its investigational ACTH receptor antagonist atumelnant.

Crinetics Pharmaceuticals’ recent ENDO 2026 updates have arrived alongside a mixed share price picture, with a 7 day share price return of 6.98% contrasting with a year to date decline of 23.24%, while the 3 year total shareholder return of 92.95% points to stronger longer term compounding.

If this kind of specialist healthcare story interests you, it could be a good moment to widen your search and check out 41 healthcare AI stocks

With Crinetics Pharmaceuticals trading at US$35.87 against an average analyst price target of US$83.14 and an indicated intrinsic discount of 91.70%, the key question is whether this reflects mispricing or if the market is already factoring in future growth.

Most Popular Narrative: 56.5% Undervalued

Based on the most followed narrative, Crinetics Pharmaceuticals’ fair value of $82.43 sits well above the last close of $35.87, which puts the latest ENDO 2026 data into a much bigger context for long term investors.

The shift in acromegaly care toward patient friendly oral therapies, combined with PALSONIFY’s positioning as a potential first medical treatment after surgery, can expand treated patient numbers across switch, naive, previously discontinued and lost to follow up groups, which would directly influence revenue growth.

Want to see what sits behind that confidence in Crinetics Pharmaceuticals? The narrative leans on aggressive revenue expansion, rising margins and a future earnings multiple that many investors would associate with fast growing leaders. Curious which specific growth path and profitability shift needs to line up for that kind of valuation to make sense? The full story spells out the numbers behind that $82.43 figure.

Result: Fair Value of $82.43 (UNDERVALUED)

However, the Crinetics Pharmaceuticals story could change quickly if PALSONIFY prescriptions disappoint or if pipeline delays persist. This would challenge the current undervalued narrative.

Next Steps

With both optimism and concern running through the Crinetics Pharmaceuticals story, it makes sense to look at the full picture and move quickly to form your own judgment based on 2 key rewards and 1 important warning sign

Looking for more investment ideas beyond Crinetics Pharmaceuticals?

If you stop with Crinetics Pharmaceuticals, you could miss other stocks that fit your style, so use the Simply Wall St screener to broaden your opportunity set.

• Target steadier potential outcomes by reviewing companies highlighted in the 66 resilient stocks with low risk scores for defensiveness and resilience.
• Hunt for strong businesses at appealing prices by scanning the 45 high quality undervalued stocks and see which stocks currently look mispriced.
• Unearth lesser known opportunities with quality fundamentals using the screener containing 20 high quality undiscovered gems before the crowd catches on.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.